Fig. 1: Number of persons treated with Alirocumab and Evolocumab.

This figure displays the number of persons treated with alirocumab and evolocumab at a given date, as well as the total number of persons in treatment, from 2016 to 2022. PCSK9: proprotein convertase subtilisin/kexin type 9.